Bespak and SNBL expand global access to an FDA-approved nasal drug delivery device

Bespak and SNBL expand global access to an FDA-approved nasal drug delivery device

Bespak and SNBL have signed an agreement to give developers of new therapies global access to a dry powder nasal delivery device.

The device will be marketed as the Air Pump Unit Dose Intranasal Powder device. It is compact, single-use and designed to deliver powdered medicine through the nose using a simple air pump.

Key advantages include:

🔹 no need for patients to coordinate breathing during use;

🔹 the ability to deliver higher drug doses;

🔹 improved drug stability and bioavailability;

🔹 more targeted delivery of medicine.

Nasal drug delivery is attracting growing interest for pain treatment, neurological and degenerative diseases, and vaccines.

The SNBL device has already been approved by the FDA as part of the Atzumi migraine treatment and is one of only a few FDA-approved dry powder nasal devices.

Bespak will combine the device with its formulation, development and manufacturing capabilities to help drug developers bring new intranasal medicines to the US and other regulated markets more quickly.